# OnCo record prostate-intermediate-risk (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/prostate-intermediate-risk/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "prostate-intermediate-risk" ;
  schema:name "Localised prostate cancer, intermediate risk"@en ;
  schema:alternateName "Intermediate-risk prostate cancer"@en, "Favourable intermediate risk"@en, "Unfavourable intermediate risk"@en, "Grade Group 2 and 3 prostate cancer"@en ;
  schema:description "Intermediate-risk prostate cancer has Grade Group 2 or 3 disease, a PSA between 10 and 20 or a tumour that fills more of the gland. Surgery or radiotherapy cure most men; the favourable half can sometimes be watched, and the unfavourable half is given a few months of hormone therapy with radiotherapy."@en ;
  schema:url <https://onco.cc/cancers/prostate-intermediate-risk/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Prostate_cancer_staging> ;
  schema:citation <https://en.wikipedia.org/wiki/Prostate_cancer_staging>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/drugs/artera-ai-prostate/>, <https://onco.cc/drugs/decipher-prostate/>, <https://onco.cc/technologies/sbrt/> ;
  onco:standardOfCare <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/trials/chhip/>, <https://onco.cc/trials/pace-b/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/drugs/leuprolide/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/trials/hypo-rt-pc/>, <https://onco.cc/drugs/artera-ai-prostate/>, <https://onco.cc/drugs/decipher-prostate/>, <https://onco.cc/technologies/digital-pathology-ai/> .